Shandong Lukang Pharmaceutical Co Ltd (600789) - Net Assets

Latest as of March 2026: CN¥5.31 Billion CNY ≈ $777.43 Million USD

Based on the latest financial reports, Shandong Lukang Pharmaceutical Co Ltd (600789) has net assets worth CN¥5.31 Billion CNY (≈ $777.43 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.88 Billion ≈ $1.45 Billion USD) and total liabilities (CN¥4.57 Billion ≈ $668.77 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Shandong Lukang Pharmaceutical Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥5.31 Billion
% of Total Assets 53.76%
Annual Growth Rate 11.65%
5-Year Change 54.64%
10-Year Change 165.22%
Growth Volatility 25.06

Shandong Lukang Pharmaceutical Co Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Shandong Lukang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore 600789 asset base for the complete picture of this company's asset base.

Annual Net Assets for Shandong Lukang Pharmaceutical Co Ltd (1993–2025)

The table below shows the annual net assets of Shandong Lukang Pharmaceutical Co Ltd from 1993 to 2025. For live valuation and market cap data, see market cap of Shandong Lukang Pharmaceutical Co Ltd.

Year Net Assets Change
2025-12-31 CN¥5.26 Billion
≈ $769.21 Million		 +29.42%
2024-12-31 CN¥4.06 Billion
≈ $594.34 Million		 +8.56%
2023-12-31 CN¥3.74 Billion
≈ $547.48 Million		 +6.68%
2022-12-31 CN¥3.51 Billion
≈ $513.21 Million		 +3.18%
2021-12-31 CN¥3.40 Billion
≈ $497.41 Million		 +1.19%
2020-12-31 CN¥3.36 Billion
≈ $491.57 Million		 +5.92%
2019-12-31 CN¥3.17 Billion
≈ $464.11 Million		 +3.26%
2018-12-31 CN¥3.07 Billion
≈ $449.48 Million		 +46.35%
2017-12-31 CN¥2.10 Billion
≈ $307.12 Million		 +5.89%
2016-12-31 CN¥1.98 Billion
≈ $290.03 Million		 +4.03%
2015-12-31 CN¥1.91 Billion
≈ $278.80 Million		 +26.66%
2014-12-31 CN¥1.50 Billion
≈ $220.11 Million		 -7.99%
2013-12-31 CN¥1.63 Billion
≈ $239.22 Million		 +1.73%
2012-12-31 CN¥1.61 Billion
≈ $235.15 Million		 -5.11%
2011-12-31 CN¥1.69 Billion
≈ $247.82 Million		 +1.01%
2010-12-31 CN¥1.68 Billion
≈ $245.35 Million		 +8.31%
2009-12-31 CN¥1.55 Billion
≈ $226.53 Million		 +3.14%
2008-12-31 CN¥1.50 Billion
≈ $219.63 Million		 +2.78%
2007-12-31 CN¥1.46 Billion
≈ $213.69 Million		 +2.69%
2006-12-31 CN¥1.42 Billion
≈ $208.09 Million		 -5.10%
2005-12-31 CN¥1.50 Billion
≈ $219.27 Million		 +0.21%
2004-12-31 CN¥1.50 Billion
≈ $218.82 Million		 -7.40%
2003-12-31 CN¥1.61 Billion
≈ $236.31 Million		 +28.18%
2002-12-31 CN¥1.26 Billion
≈ $184.36 Million		 +8.45%
2001-12-31 CN¥1.16 Billion
≈ $170.00 Million		 +2.77%
2000-12-31 CN¥1.13 Billion
≈ $165.42 Million		 +2.78%
1999-12-31 CN¥1.10 Billion
≈ $160.95 Million		 -1.82%
1998-12-31 CN¥1.12 Billion
≈ $163.93 Million		 +26.58%
1997-12-31 CN¥885.05 Million
≈ $129.51 Million		 +120.24%
1996-12-31 CN¥401.85 Million
≈ $58.80 Million		 +28.40%
1995-12-31 CN¥312.96 Million
≈ $45.80 Million		 +68.13%
1994-12-31 CN¥186.15 Million
≈ $27.24 Million		 +20.24%
1993-12-31 CN¥154.81 Million
≈ $22.65 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Shandong Lukang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 206617.4% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥1.14 Billion 22.33%
Other Components CN¥3.97 Billion 77.67%
Total Equity CN¥5.11 Billion 100.00%

Shandong Lukang Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Shandong Lukang Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Dowlais Group Plc
LSE:DWL
 $1.24 Billion
Dogan Sirketler Grubu Holding AS
IS:DOHOL
 $1.24 Billion
Fiyta Holdings Ltd
SHE:000026
 $1.24 Billion
Hangzhou MDK Opto Electronic Corp. Ltd. A
SHG:688079
 $1.24 Billion
Ningbo Construction Co Ltd
SHG:601789
 $1.24 Billion
Shaanxi Provincial Natural Gas Co Ltd
SHE:002267
 $1.24 Billion
Vimeo Inc
NASDAQ:VMEO
 $1.24 Billion
Tuya Inc ADR
NYSE:TUYA
 $1.24 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shandong Lukang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 3,918,185,000 to 5,114,660,477, a change of 1,196,475,477 (30.5%).
  • Net income of 112,304,824 contributed positively to equity growth.
  • Dividend payments of 166,297,756 reduced retained earnings.
  • Other factors increased equity by 1,250,468,409.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥112.30 Million +2.2%
Dividends Paid CN¥166.30 Million -3.25%
Other Changes CN¥1.25 Billion +24.45%
Total Change CN¥- 30.54%

Book Value vs Market Value Analysis

This analysis compares Shandong Lukang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.66x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 44.22x to 1.66x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.18 CN¥8.11 x
1994-12-31 CN¥0.22 CN¥8.11 x
1995-12-31 CN¥0.26 CN¥8.11 x
1996-12-31 CN¥0.48 CN¥8.11 x
1997-12-31 CN¥1.05 CN¥8.11 x
1998-12-31 CN¥1.33 CN¥8.11 x
1999-12-31 CN¥1.30 CN¥8.11 x
2000-12-31 CN¥1.34 CN¥8.11 x
2001-12-31 CN¥1.38 CN¥8.11 x
2002-12-31 CN¥2.35 CN¥8.11 x
2003-12-31 CN¥3.02 CN¥8.11 x
2004-12-31 CN¥2.80 CN¥8.11 x
2005-12-31 CN¥2.80 CN¥8.11 x
2006-12-31 CN¥2.49 CN¥8.11 x
2007-12-31 CN¥2.08 CN¥8.11 x
2008-12-31 CN¥1.94 CN¥8.11 x
2009-12-31 CN¥1.87 CN¥8.11 x
2010-12-31 CN¥2.15 CN¥8.11 x
2011-12-31 CN¥2.56 CN¥8.11 x
2012-12-31 CN¥2.01 CN¥8.11 x
2013-12-31 CN¥2.16 CN¥8.11 x
2014-12-31 CN¥1.90 CN¥8.11 x
2015-12-31 CN¥1.76 CN¥8.11 x
2016-12-31 CN¥2.45 CN¥8.11 x
2017-12-31 CN¥2.64 CN¥8.11 x
2018-12-31 CN¥3.45 CN¥8.11 x
2019-12-31 CN¥3.43 CN¥8.11 x
2020-12-31 CN¥3.53 CN¥8.11 x
2021-12-31 CN¥3.70 CN¥8.11 x
2022-12-31 CN¥3.65 CN¥8.11 x
2023-12-31 CN¥4.03 CN¥8.11 x
2024-12-31 CN¥4.37 CN¥8.11 x
2025-12-31 CN¥4.89 CN¥8.11 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shandong Lukang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.20%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 1.95%
  • • Asset Turnover: 0.57x
  • • Equity Multiplier: 1.96x
  • Recent ROE (2.20%) is below the historical average (5.55%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 20.86% 8.14% 0.98x 2.62x CN¥16.81 Million
1994 32.89% 14.09% 0.97x 2.42x CN¥42.60 Million
1995 29.68% 13.53% 0.77x 2.84x CN¥43.74 Million
1996 21.33% 14.35% 0.76x 1.96x CN¥45.53 Million
1997 10.68% 13.69% 0.52x 1.50x CN¥6.06 Million
1998 5.25% 10.45% 0.36x 1.39x CN¥-53.16 Million
1999 4.21% 7.81% 0.33x 1.63x CN¥-63.72 Million
2000 5.03% 8.10% 0.31x 2.01x CN¥-56.24 Million
2001 6.07% 9.14% 0.32x 2.05x CN¥-45.71 Million
2002 7.66% 9.28% 0.44x 1.87x CN¥-29.48 Million
2003 3.35% 5.56% 0.36x 1.67x CN¥-107.37 Million
2004 -6.18% -8.99% 0.38x 1.80x CN¥-241.89 Million
2005 0.33% 0.43% 0.45x 1.73x CN¥-144.87 Million
2006 -6.79% -8.67% 0.46x 1.71x CN¥-238.67 Million
2007 1.78% 1.85% 0.56x 1.72x CN¥-119.98 Million
2008 2.38% 2.03% 0.69x 1.69x CN¥-112.82 Million
2009 2.47% 1.93% 0.78x 1.63x CN¥-114.84 Million
2010 7.86% 5.90% 0.73x 1.83x CN¥-35.25 Million
2011 0.90% 0.64% 0.67x 2.09x CN¥-151.26 Million
2012 -8.81% -5.72% 0.59x 2.62x CN¥-285.70 Million
2013 0.71% 0.49% 0.54x 2.67x CN¥-141.89 Million
2014 -8.89% -5.42% 0.57x 2.90x CN¥-266.10 Million
2015 0.44% 0.33% 0.60x 2.22x CN¥-173.12 Million
2016 1.57% 1.16% 0.60x 2.25x CN¥-156.43 Million
2017 5.83% 4.39% 0.50x 2.66x CN¥-81.55 Million
2018 5.51% 4.85% 0.51x 2.24x CN¥-131.33 Million
2019 4.01% 3.25% 0.53x 2.35x CN¥-180.86 Million
2020 7.09% 5.42% 0.58x 2.26x CN¥-93.52 Million
2021 2.74% 1.81% 0.63x 2.39x CN¥-236.30 Million
2022 4.11% 2.46% 0.64x 2.60x CN¥-197.67 Million
2023 6.82% 4.00% 0.70x 2.44x CN¥-115.00 Million
2024 10.07% 6.33% 0.69x 2.32x CN¥2.80 Million
2025 2.20% 1.95% 0.57x 1.96x CN¥-399.16 Million

Industry Comparison

This section compares Shandong Lukang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $4,930,657,086
  • Average return on equity (ROE) among peers: -19.69%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Shandong Lukang Pharmaceutical Co Ltd (600789) CN¥5.31 Billion 20.86% 0.86x $1.24 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $1.06 Billion 5.59% 4.55x $662.23 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $753.81 Million 5.52% 0.69x $403.91 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.26 Billion 16.30% 0.27x $4.68 Billion
Livzon Pharmaceutical Group Inc (000513) $2.23 Billion 21.64% 0.40x $2.67 Billion
Wedge Industrial Co Ltd (000534) $596.67 Million 0.77% 0.03x $2.67 Billion
Yunnan Baiyao Group Co Ltd (000538) $39.91 Billion 10.26% 0.35x $13.09 Billion
Hainan Haiyao Co Ltd (000566) $590.38 Million -258.34% 9.36x $810.64 Million
Tus Pharmaceutical Group Co Ltd (000590) $271.26 Million 1.07% 1.01x $357.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $2.40 Billion -16.01% 2.62x $1.01 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $243.07 Million 16.30% 0.73x $3.07 Billion

About Shandong Lukang Pharmaceutical Co Ltd

SHG:600789 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.24 Billion
CN¥8.48 Billion CNY
Market Cap Rank
#8203 Global
#2056 in China
Share Price
CN¥8.11
Change (1 day)
-1.34%
52-Week Range
CN¥7.89 - CN¥11.10
All Time High
CN¥16.22
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Shandong Lukang Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in China. The company provides analgesics and antipyretics; gastrointestinal; endocrine; cardio-cerebrovascular; anti-infective; and other human formulation products. It offers human and veterinary active pharmaceutical ingredient; veterinary formulation; bio-pesticides; and amino acid. The company also exports its produ… Read more